Citations

Mayo Clinic

Showing 10 of 108522 citations.

Correction for Tesfay et al., Vesiculovirus Neutralization by Natural IgM and Complement
Tesfay, Mulu Z. , Ammayappan, Arun , Federspiel, Mark J. , Barber, Glen N. , Stojdl, David F., Peng, Kah-Whye , Russell, Stephen J. , Russell, Stephen J

Journal of Virology | January 12, 2015 | Volume: 89 | Issue: 3 | Pages: 1945-1946

10.1128/jvi.03326-14 Get It

Evidence gaps in the management of sickle cell disease: A summary of needed research
Savage, William, Buchanan, George R., Yawn, Barbara P. , Afenyi‐Annan, Araba, Ballas, Samir K. , Goldsmith, Jonathan C. , James, Allison , John‐Sowah, Joylene, Jordan, Lanetta, Lottenberg, Richard , Murad, M. Hassan , Ortíz, Eduardo , Tanabe, Paula , Lanzkron, Sophie , Hassell, Kathryn Louise , Ware, Russell E. , Murad, M Hassan , James, Andra H

American Journal of Hematology | January 12, 2015 | Volume: 90 | Issue: 4 | Pages: 273-275

10.1002/ajh.23945 | PMID 25639238 Get It

Integration of Architectural and Cytologic Driven Image Algorithms for Prostate Adenocarcinoma Identification
Hipp, Jason, Monaco, James , Kunju, Lakshmi P., Cheng, Jerome , Yagi, Yukako , Emmert‐Buck, Michael R., Tomaszewski, John E. , Tompkins, Ronald G. , Flotte, Thomas J. , Lucas, David R. , Gilbertson, John R. , Rodriguez‐Canales, Jaime , Hewitt, Stephen M. , Feldman, Michael D. , Toner, Mehmet , Madabhushi, Anant , Balis, Ulysses J.

Analytical Cellular Pathology | January 12, 2015 | Volume: 35 | Issue: 4 | Pages: 251-265

10.1155/2012/294358 Get It

Introduction: The advent of digital slides offers new opportunities within the practice of pathology such as the use of image analysis techniques to facilitate computer aided diagnosis (CAD) solutions. Use of CAD holds promise to enable new levels of decision support and allow for additional layers of quality assurance and consistency in rendered diagnoses. However, the development and testing of prostate cancer CAD solutions requires a ground truth map of the cancer to enable the generation of receiver operator characteristic (ROC) curves. This requires a pathologist to annotate, or paint, each of the malignant glands in prostate cancer with an image editor software - a time consuming and exhaustive process.Recently, two CAD algorithms have been described: probabilistic pairwise Markov models (PPMM) and spatially-invariant vector quantization (SIVQ). Briefly, SIVQ operates as a highly sensitive and specific pattern matching algorithm, making it optimal for the identification of any epithelial morphology, whereas PPMM operates as a highly sensitive detector of malignant perturbations in glandular lumenal architecture.Methods: By recapitulating algorithmically how a pathologist reviews prostate tissue sections, we created an algorithmic cascade of PPMM and SIVQ algorithms as previously described by Doyle el al. [1] where PPMM identifies the glands with abnormal lumenal architecture, and this area is then screened by SIVQ to identify the epithelium.Results: The performance of this algorithm cascade was assessed qualitatively (with the use of heatmaps) and quantitatively (with the use of ROC curves) and demonstrates greater performance in the identification of malignant prostatic epithelium.Conclusion: This ability to semi-autonomously paint nearly all the malignant epithelium of prostate cancer has immediate applications to future prostate cancer CAD development as a validated ground truth generator. In addition, such an approach has potential applications as a pre-screening/quality assurance tool.
Association between health‐related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride
Tack, Jan , Camilleri, Michael , Vandeplassche, Lieve, Joseph, Alain, Kerstens, René, DuBois, David Lane , Tack, Jan

Neurogastroenterology & Motility | January 12, 2015 | Volume: 27 | Issue: 3 | Pages: 397-405

10.1111/nmo.12505 | PMID 25581251 Get It

AbstractBackgroundPrucalopride is a high‐affinity 5‐HT4 receptor agonist for the treatment of chronic constipation. The aims of this study were to investigate the relationship between health‐related quality of life (HRQoL) and symptoms of constipation, and to assess the response of HRQoL to treatment using integrated data from three phase III trials of prucalopride.MethodsThis was an integrated analysis of data from three pivotal multicenter, double‐blind, randomized, placebo‐controlled, parallel‐group trials (ClinicalTrials.gov Identifiers: NCT00488137, NCT00483886 and NCT00485940). Relationships were investigated between Patient Assessment of Constipation Quality of Life (PAC‐QOL) scores, Patient Assessment of Constipation Symptoms (PAC‐SYM) scores, bowel movement frequency (assessed using daily diaries), and treatment.Key ResultsPatients treated with prucalopride 2 mg (n = 659) and placebo (n = 661) were included in the analysis. An improvement in PAC‐SYM scores correlated well with an improvement in PAC‐QOL overall score (r = 0.711) and satisfaction subscale score (r = 0.589). After 12 weeks, PAC‐QOL overall score and satisfaction subscale score significantly (p < 0.001) improved by ≥1 point (clinically relevant) in 36.5% and 44.1% of patients treated with prucalopride, compared with 18.5% and 22.4% with placebo respectively. Moreover, 39.0% of patients with an improvement in satisfaction of ≥1 point achieved ≥3 spontaneous complete bowel movements/week, compared with 7.4% of those with no improvement in satisfaction (<1 point).Conclusions & InferencesImprovements in PAC‐QOL overall score and satisfaction score were associated with improvements in symptoms of chronic constipation. Compared with placebo, treatment with prucalopride significantly improved HRQoL.
Bedside diagnosis of dysphagia: A systematic review
O’Horo, John C. , Rogus‐Pulia, Nicole , Garcia‐Arguello, Lisbeth, Robbins, JoAnne, Safdar, Nasia , Garcia-Arguello, Lisbeth, O'Horo, John C

Journal of Hospital Medicine | January 12, 2015 | Volume: 10 | Issue: 4 | Pages: 256-265

10.1002/jhm.2313 | PMID 25581840 Get It

Dysphagia is associated with aspiration, pneumonia, and malnutrition, but remains challenging to identify at the bedside. A variety of exam protocols and maneuvers are commonly used, but the efficacy of these maneuvers is highly variable. We conducted a comprehensive search of 7 databases, including MEDLINE, Embase, and Scopus, from each database's earliest inception through June 9, 2014. Studies reporting diagnostic performance of a bedside examination maneuver compared to a reference gold standard (videofluoroscopic swallow study or flexible endoscopic evaluation of swallowing with sensory testing) were included for analysis. From each study, data were abstracted based on the type of diagnostic method and reference standard study population and inclusion/exclusion characteristics, design, and prediction of aspiration. The search strategy identified 38 articles meeting inclusion criteria. Overall, most bedside examinations lacked sufficient sensitivity to be used for screening purposes across all patient populations examined. Individual studies found dysphonia assessments, abnormal pharyngeal sensation assessments, dual axis accelerometry, and 1 description of water swallow testing to be sensitive tools, but none were reported as consistently sensitive. A preponderance of identified studies was in poststroke adults, limiting the generalizability of results. No bedside screening protocol has been shown to provide adequate predictive value for presence of aspiration. Several individual exam maneuvers demonstrated reasonable sensitivity, but reproducibility and consistency of these protocols was not established. More research is needed to design an optimal protocol for dysphagia detection. Journal of Hospital Medicine 2015;10:256–265. © 2015 Society of Hospital Medicine
Acute Contained Ruptured Aortic Aneurysm Presenting as Left Vocal Fold Immobility
Gnagi, Sharon H. , Howard, Brittany E. , Hoxworth, Joseph M. , Lott, David G.

Case Reports in Otolaryngology | January 11, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-3

10.1155/2015/219090 | PMID 25648215 Get It

Objective. To recognize intrathoracic abnormalities, including expansion or rupture of aortic aneurysms, as a source of acute onset vocal fold immobility.Methods. A case report and review of the literature.Results. An 85-year-old female with prior history of an aortic aneurysm presented to a tertiary care facility with sudden onset hoarseness. On laryngoscopy, the left vocal fold was immobile in the paramedian position. A CT scan obtained that day revealed a new, large hematoma surrounding the upper descending aortic stent graft consistent with an acute contained ruptured aortic aneurysm. She was referred to the emergency department for evaluation and treatment by vascular surgery. She was counseled regarding surgical options and ultimately decided not to pursue further treatment. Her vocal fold immobility was subsequently treated via office-based injection medialization two weeks after presentation and again 5 months after the initial injection which dramatically improved her voice. Follow-up CT scan at 8 months demonstrated a reduction of the hematoma. The left vocal cord remains immobile to date.Conclusion. Ortner’s syndrome, or cardiovocal syndrome, is hoarseness secondary to left recurrent laryngeal nerve palsy caused by cardiovascular pathology. It is a rare condition and, while typically presenting gradually, may also present with acute symptomatology.
Percutaneous Epicardial Access for Mapping and Ablation Is Feasible in Patients With Prior Cardiac Surgery, Including Coronary Bypass Surgery
Killu, Ammar M. , Ebrille, Elisa , Asirvatham, Samuel J. , Munger, Thomas M. , Packer, Douglas L. , Friedman, Paul A. , Mulpuru, Siva K. , McLeod, Christopher J. , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | January 10, 2015 | Volume: 8 | Issue: 1 | Pages: 94-101

10.1161/circep.114.002349 | PMID 25575533 Get It

Background— Prior cardiac surgery, especially the presence of coronary artery bypass grafts, is thought to preclude percutaneous epicardial access (EpiAcc) and, therefore, mapping and ablation. We evaluated the feasibility and safety of EpiAcc in patients with a prior cardiac operation. Methods and Results— We retrospectively analyzed all patients who underwent EpiAcc for ablation for ventricular tachycardia or symptomatic premature ventricular complexes between 2004 and 2013 at Mayo Clinic, Rochester, MN. Of 162 patients who underwent EpiAcc, 18 had prior cardiac surgery (median age, 64 years, all men). This included 10 coronary artery bypass grafts, 2 epicardial implantable cardioverter defibrillator placement, 5 valve surgery, 2 septal myectomy, 1 aortic arch replacement, 1 myocardial bridge unroofing, and 1 myocardial perforation repair (3 patients had multiple procedures). Access was successful in 12 of 18; the inferior approach was used in 78%. Successful access was achieved in 6 of 10 patients with prior coronary artery bypass grafts. Adhesiolysis was required in 10 patients with the sheath, access wire, and pigtail or ablation catheter. Intraprocedural coronary angiography was performed in 8 patients. A total of 45 ventricular tachycardias/premature ventricular complexes were ablated. Thirteen patients underwent endocardial-only ablation, 2 had epicardial-only ablation, whereas 3 had endocardial–epicardial ablation. Ablation was deemed successful in 13 of 18 patients. Four patients had bleeding complications (pericardial effusion, pericardial hematoma, hemoperitoneum, and pericardial tamponade). In patients with coronary grafts, there was no evidence of acute graft disruption. Conclusions— Percutaneous EpiAcc is feasible in patients with previous cardiac surgery, including coronary artery bypass grafts. However, adhesiolysis is frequently required. Although the risk of coronary graft injury is low, life-threatening complications may occur.
Pharmacogenomics of Hypertension: A Genome‐Wide, Placebo‐Controlled Cross‐Over Study, Using Four Classes of Antihypertensive Drugs
Hiltunen, Timo P. , Donner, Kati , Sarin, Antti‐Pekka, Saarela, Janna , Chapman, Arlene B. , Gums, John G. , Frau, Francesca , Glorioso, Valeria, Zaninello, Roberta, Salvi, Erika , Glorioso, Nicola, Boerwinkle, Eric , Johnson, Julie A. , Kontula, Kimmo , Ripatti, Samuli , Gong, Yan , Cooper‐DeHoff, Rhonda M. , Turner, Stephen T.

Journal of the American Heart Association | January 10, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.1161/jaha.114.001521 Get It

Background Identification of genetic markers of antihypertensive drug responses could assist in individualization of hypertension treatment. Methods and Results We conducted a genome‐wide association study to identify gene loci influencing the responsiveness of 228 male patients to 4 classes of antihypertensive drugs. The Genetics of Drug Responsiveness in Essential Hypertension ( GENRES ) study is a double‐blind, placebo‐controlled cross‐over study where each subject received amlodipine, bisoprolol, hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order. Replication analyses were performed in 4 studies with patients of European ancestry ( PEAR Study, N=386; GERA I and II Studies, N=196 and N=198; SOPHIA Study, N=372). We identified 3 single‐nucleotide polymorphisms within the ACY 3 gene that showed associations with bisoprolol response reaching genome‐wide significance ( P <5×10 −8 ); however, this could not be replicated in the PEAR Study using atenolol. In addition, 39 single‐nucleotide polymorphisms showed P values of 10 −5 to 10 −7 . The 20 top‐associated single‐nucleotide polymorphisms were different for each antihypertensive drug. None of these top single‐nucleotide polymorphisms co‐localized with the panel of >40 genes identified in genome‐wide association studies of hypertension. Replication analyses of GENRES results provided suggestive evidence for a missense variant (rs3814995) in the NPHS 1 (nephrin) gene influencing losartan response, and for 2 variants influencing hydrochlorothiazide response, located within or close to the ALDH 1A3 (rs3825926) and CLIC 5 (rs321329) genes. Conclusions These data provide some evidence for a link between biology of the glomerular protein nephrin and antihypertensive action of angiotensin receptor antagonists and encourage additional studies on aldehyde dehydrogenase–mediated reactions in antihypertensive drug action.
Airway responsiveness in CD38-deficient mice in allergic airway disease: studies with bone marrow chimeras
Guedes, Alonso , Jude, Joseph A. , Paulin, Jaime , Rivero-Nava, Laura, Kita, Hirohito , Lund, Frances E. , Kannan, Mathur , Kita, H

American Journal of Physiology-Lung Cellular and Molecular Physiology | January 10, 2015 | Volume: 308 | Issue: 5 | Pages: L485-L493

10.1152/ajplung.00227.2014 | PMID 25575514 Get It

CD38 is a cell-surface protein involved in calcium signaling and contractility of airway smooth muscle. It has a role in normal airway responsiveness and in airway hyperresponsiveness (AHR) developed following airway exposure to IL-13 and TNF-α but appears not to be critical to airway inflammation in response to the cytokines. CD38 is also involved in T cell-mediated immune response to protein antigens. In this study, we assessed the contribution of CD38 to AHR and inflammation to two distinct allergens, ovalbumin and the epidemiologically relevant environmental fungus Alternaria. We also generated bone marrow chimeras to assess whether Cd38+/+inflammatory cells would restore AHR in the CD38-deficient ( Cd38−/−) hosts following ovalbumin challenge. Results show that wild-type (WT) mice develop greater AHR to inhaled methacholine than Cd38−/−mice following challenge with either allergen, with comparable airway inflammation. Reciprocal bone marrow transfers did not change the native airway phenotypic differences between WT and Cd38−/−mice, indicating that the lower airway reactivity of Cd38−/−mice stems from Cd38−/−lung parenchymal cells. Following bone marrow transfer from either source and ovalbumin challenge, the phenotype of Cd38−/−hosts was partially reversed, whereas the airway phenotype of the WT hosts was preserved. Airway inflammation was similar in Cd38−/−and WT chimeras. These results indicate that loss of CD38 on hematopoietic cells is not sufficient to prevent AHR and that the magnitude of airway inflammation is not the predominant underlying determinant of AHR in mice.
H odgkin transformation of chronic lymphocytic leukemia: I ncidence, outcomes, and comparison to de novo H
Chaffee, Kari G. , Call, Timothy G. , Leis, José F., Macon, William R. , Schwager, Susan M., Ristow, Kay M., Porrata, Luis F. , Rabe, Kari G. , Parikh, Sameer A. , Habermann, Thomas M. , Ding, Wei , Kay, Neil E. , Slager, Susan L. , Shanafelt, Tait D.

American Journal of Hematology | January 10, 2015 | Volume: 90 | Issue: 4 | Pages: 334-338

10.1002/ajh.23939 | PMID 25581025 Get It

Although transformation to Hodgkin lymphoma (HL) is a recognized complication in patients with chronic lymphocytic leukemia (CLL), its incidence, clinical characteristics and outcomes are not well defined. We used the Mayo Clinic CLL and Lymphoma Databases to identify CLL patients who developed biopsy‐proven HL (CLL/HL) on follow‐up, as well as cases of de novo HL (i.e., without prior CLL). Among 3887 CLL patients seen at Mayo Clinic from January 1995 through August 2011, 26 (0.7%) developed HL. In a nested cohort of 2,465 newly diagnosed CLL patients followed prospectively, the incidence of HL was 0.05%/year (10 year risk = 0.5%). The median overall survival (OS) from date of HL diagnosis in patients with CLL/HL was 3.9 years compared to not reached for de novo HL patients ( n = 709) seen during the same time interval ( P < 0.001). The shorter OS of CLL/HL patients persisted after adjusting for differences in age and Ann Arbor stage of disease. The International Prognostic score (IPS) developed for de novo HL stratified prognosis among CLL/HL patients with median survival of not reached, 6.2, 2.4, and 0.3 years ( P = 0.006) for those with IPS scores of ≤2, 3, 4, and ≥5, respectively. In summary, approximately 1 of every 200 CLL patients will develop HL within 10 years. Survival after HL diagnosis in patients with CLL is shorter than de novo HL patients. The IPS for de novo HL may be useful for stratifying survival in CLL/HL patients. Am. J. Hematol. 90:334–338, 2015. © 2015 Wiley Periodicals, Inc.